Insulin Glargine (Semglee) is Biocon-Mylans third biosimilar to be approved by the USFDA in a span of 24 months. Considering two competitors (Innovator- Sanofi; Biosimilar by Eli Lilly/Boehringer Ingelheim team; EL/BI) are already in the market and Biocon-Mylan are the third to get USFDA approval with other peers still under clinical phase, we expect Biocon (BIOS) to garner USD130m on an annualized basis from this opportunity, post commercialization in 2HFY21. BIOS recently received the USFDAs approval for its Insulin Glargine (biosimilar version Semglee) for both versions (vial and pen). Further, BIOS-Mylan has recently won a favorable ruling from the US Patent and Trial Board (USPTAB) in the patent litigation against Sanofi for 4 device patents for Lantus SoloSTAR. Moreover, in Mar20, the US district Court of New Jersey ruled that Sanofis 844 patent (product patent) was not infringed by Mylans Insulin Glargine product.